U.S. pharma huge copyright scrapped two experimental weight loss drugs very last year—a after-day-to-day capsule, lotiglipron, as a result of elevated liver enzymes along with a twice-day-to-day pill, danuglipron, resulting from solid Negative effects—but CEO Albert Bourla has said t